Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Tungsten Surge Positions Almonty for Breakout Growth

Robert Sasse by Robert Sasse
November 7, 2025
in Analysis, Commodities, Penny Stocks
0
Almonty Stock
0
SHARES
21
VIEWS
Share on FacebookShare on Twitter

A powerful combination of bullish analyst sentiment and record-breaking commodity prices is creating exceptional momentum for Almonty Industries. The Canadian tungsten producer is capturing investor attention as market dynamics shift dramatically in its favor.

Record Commodity Prices and Upgraded Forecasts

The global tungsten market is experiencing unprecedented strength, with prices recently surging past $61,500 per metric ton. This remarkable price appreciation coincides with significantly upgraded financial projections from B. Riley analysts. The research firm substantially raised its earnings outlook for Almonty, boosting the 2026 forecast from $0.21 to $0.24 per share. Even more impressive are the projections for subsequent years, with anticipated earnings of $0.81 per share in 2027 and $1.28 per share in 2028, signaling extraordinary growth potential.

These optimistic assessments reflect fundamental supply and demand imbalances reshaping the tungsten sector. China, historically the dominant global producer, is confronting significant production constraints. Simultaneously, demand from defense contractors, renewable energy developers, and high-technology manufacturers continues to accelerate. Chinese sources confirmed substantial price increases for tungsten concentrate earlier this week, underscoring the market’s tightening conditions.

Strategic Positioning and Operational Milestones

Almonty’s timing appears impeccable as it transitions toward full-scale production at its flagship Sangdong mine in South Korea. Company officials announced that construction is “substantially complete,” with commercial production expected to commence imminently. Once fully operational, Sangdong will become the largest tungsten mine outside Chinese control, providing a strategic Western alternative in a geopolitically sensitive industry.

Should investors sell immediately? Or is it worth buying Almonty?

The company’s recent operational performance further validates its growth trajectory. Third-quarter results released last Sunday revealed a 28% revenue increase to $8.7 million, driven by stronger tungsten pricing and consistent output from its operating Panasqueira mine in Portugal.

Capital Markets and Expansion Strategy

Almonty has strengthened its financial position through strategic capital market activities. The company’s successful Nasdaq listing in July generated $90 million in proceeds, followed by the strategic acquisition of the Genting Browns Lake tungsten project in Montana in late October.

Market experts overwhelmingly recommend the shares with “Strong Buy” ratings. Trading around its 200-day average of CA$5.77, the stock has demonstrated substantial appreciation. Investor focus now centers on the final commissioning phase at Sangdong—a development that could establish Almonty as a pivotal competitor in the global tungsten market.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from March 25 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

March 25, 2026
Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Next Post
Intel Stock

Intel's Rollercoaster: A Deceptive Rally Meets Harsh Reality

Ocugen Stock

Ocugen's Financial Health Sparks Investor Concern Amid Aggressive R&D Push

Procter & Gamble Stock

Procter & Gamble Shares: A Market Conundrum Amid Strong Fundamentals

Recommended

Amazon Stock

Amazon Faces Regulatory Setback While Pushing AI and Retail Expansion

6 months ago
Energy Vault Holdings Stock

Energy Vault’s Strategic Pivot Gains Momentum with Major Texas Acquisition

5 months ago
COREWEAVE INC-CL A Stock

CoreWeave Shares Face Critical Earnings Test

5 months ago
Uranium Energy Stock

Uranium Energy Stock: A Market Paradox

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Ocugen Shares Slide Despite Positive Clinical Trial Results

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Trending

Energiekontor Stock
Energy & Oil

Energiekontor Stock Gains Momentum from Policy Shifts

by Rodolfo Hanigan
March 25, 2026
0

While Energiekontor's share price has faced significant headwinds this year, declining roughly 12% since January and over...

Bionxt Solutions Stock

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

March 25, 2026
Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Energiekontor Stock Gains Momentum from Policy Shifts
  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com